Compounds > 5-amino-2,4-dihydroxy-alpha-methylphenylethylamine
Page last updated: 2024-12-07

5-amino-2,4-dihydroxy-alpha-methylphenylethylamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID129444
CHEMBL ID132012
MeSH IDM0197067

Synonyms (10)

Synonym
4-amino-6-(2-amino-propyl)-benzene-1,3-diol
bdbm50031348
5-admp
CHEMBL132012 ,
4-amino-6-(2-aminopropyl)benzene-1,3-diol
5-amino-2,4-dihydroxy-alpha-methylphenylethylamine
106868-44-4
1,3-benzenediol, 4-amino-6-(2-aminopropyl)-
1-(5-amino-2,4-dihydroxyphenyl)-2-aminopropane
DTXSID20910157
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)Ki0.11200.00030.37088.1600AID65474
TransporterRattus norvegicus (Norway rat)Ki0.04600.00010.866710.0000AID145874
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (40)

Assay IDTitleYearJournalArticle
AID139835Noradrenergic effect was determined by depletion effect of Nerepinephrine (NE) in mouse brain regions expressed as d501995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID65474Evaluated for the Competitive inhibition of uptake of dopamine transporter1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139661Long term depletion of Dopamine(DA) in Whole mouse Brain region of medulla-pons at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139813Long term depletion of Norepinephrine (NE) in Whole mouse Brain, region of midbrain at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139836Noradrenergic effect was determined by depletion effect of Serotonin(5-HT) in mouse brain regions expressed as d501995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139818Long term depletion of Serotonin(5-HT) in Whole mouse Brain region of cortex at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139839Noradrenergic effect was determined by depletion effect of Serotonin(5-HT) in mouse brain regions expressed as log d501995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID175698Evaluated for the stimulation of synaptosomal release of norepinephrine (release constant)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139837Noradrenergic effect was determined by depletion effect of Dopamine(DA) in mouse brain regions expressed as log d501995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139820Long term depletion of Serotonin(5-HT) in Whole mouse Brain region of hypothalamus at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139668Long term depletion of Norepinephrine (NE) in Whole mouse Brain region of cerebellum at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139819Long term depletion of Serotonin(5-HT) in Whole mouse Brain region of hippocampus at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139838Noradrenergic effect was determined by depletion effect of Nerepinephrine (NE) in mouse brain regions expressed as log d501995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139666Long term depletion of Norepinephrine (NE) in Whole mouse Brain at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139658Long term depletion of Dopamine(DA) in Whole mouse Brain region of hippocampus at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139667Long term depletion of Norepinephrine (NE) in Whole mouse Brain at a low dose (60 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139654Long term depletion of Dopamine(DA) in Whole mouse Brain at a low dose (60 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139823Long term depletion of Serotonin(5-HT) in Whole mouse Brain region of striatum at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139664Long term depletion of Dopamine(DA) in Whole mouse Brain region of thalamus at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139653Long term depletion of Dopamine(DA) in Whole mouse Brain at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139808Long term depletion of Norepinephrine (NE) in Whole mouse Brain region of hypothalamus at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139821Long term depletion of Serotonin(5-HT) in Whole mouse Brain region of medulla-pons at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139816Long term depletion of Serotonin(5-HT) in Whole mouse Brain at a low dose (60 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139834Noradrenergic effect was determined by depletion effect of Dopamine(DA) in mouse brain regions expressed as d501995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID145874Evaluated for the Competitive inhibition of uptake of norepinephrine1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139815Long term depletion of Serotonin(5-HT) in Whole mouse Brain at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID175697Evaluated for the stimulation of synaptosomal release of Dopamine (release constant)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139825Long term depletion of Serotonin(5-HT) in Whole mouse Brain, region of midbrain at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139812Long term depletion of Norepinephrine (NE) in Whole mouse Brain region of thalamus at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139657Long term depletion of Dopamine(DA) in Whole mouse Brain region of cortex at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139809Long term depletion of Norepinephrine (NE) in Whole mouse Brain region of medulla-pons at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139806Long term depletion of Norepinephrine (NE) in Whole mouse Brain region of hippocampus at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139663Long term depletion of Dopamine(DA) in Whole mouse Brain region of striatum at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139811Long term depletion of Norepinephrine (NE) in Whole mouse Brain region of striatum at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139655Long term depletion of Dopamine(DA) in Whole mouse Brain region of cerebellum at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139817Long term depletion of Serotonin(5-HT) in Whole mouse Brain region of cerebellum at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139824Long term depletion of Serotonin(5-HT) in Whole mouse Brain region of thalamus at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139665Long term depletion of Dopamine(DA) in Whole mouse Brain, region of midbrain at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139659Long term depletion of Dopamine(DA) in Whole mouse Brain region of hypothalamus at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
AID139804Long term depletion of Norepinephrine (NE) in Whole mouse Brain region of cortex at a high dose (300 nmol)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's8 (80.00)18.2507
2000's2 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.76 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
benoxathian
benoxathian: RN given refers to parent cpd; structure given in first source		1.9910
oxidopamine
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.. oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).		1.9810benzenetriol;
catecholamine;
primary amino compound		drug metabolite;
human metabolite;
neurotoxin
propranolol
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.		1.9710naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
phenylephrine
Phenylephrine: An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent.. phenylephrine : A member of the class of the class of phenylethanolamines that is (1R)-2-(methylamino)-1-phenylethan-1-ol carrying an additional hydroxy substituent at position 3 on the phenyl ring.		1.9710phenols;
phenylethanolamines;
secondary amino compound		alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent
2,4,5-trihydroxyamphetamine
2,4,5-trihydroxyamphetamine: structure given in first source; an in vitro metabolite of 2-hydroxy-4,5-(methylenedioxy)amphetamine		1.9810
6-aminodopamine
6-aminodopamine: cytotoxic agent; RN given refers to parent cpd; structure		1.9810
oxytocin
Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.		3.0950heterodetic cyclic peptide;
peptide hormone		oxytocic;
vasodilator agent
ibutamoren mesylate
ibutamoren mesylate: a growth hormone secretagogue; structure in first source		210
sincalide
Sincalide: An octapeptide hormone present in the intestine and brain. When secreted from the gastric mucosa, it stimulates the release of bile from the gallbladder and digestive enzymes from the pancreas.		1.9810oligopeptide
pituitrin
Pituitrin: A substance or extract from the neurohypophysis (PITUITARY GLAND, POSTERIOR).		2.6830
ConditionIndicatedRelationship StrengthStudiesTrials